France
X-PRESSURE, founded in 2022 and headquartered in France, is pioneering advancements in the management of normal pressure hydrocephalus (NPH) through its innovative medical device, the XP One. Targeting a significant issue in neurological care, X-PRESSURE aims to significantly reduce the currently high rates of undiagnosed or misdiagnosed NPH cases, leveraging its cutting-edge cerebrospinal fluid (CSF) infusion testing technology.
The device provides real-time, smart CSF testing, revolutionizing bedside diagnostics with improved accuracy and speed. By offering a standardized approach to NPH detection, X-PRESSURE is set to empower clinicians—potentially leading to superior patient outcomes.
The company has attracted substantial investor confidence, securing a €4.50M Seed Round in June 2023 from notable investors including Bpifrance, M Capital Partners, and IRDI SORIDEC Gestion. Operating within the Manufacturing and Medical Devices industries, X-PRESSURE is well-positioned to capitalize on its innovative approach and robust support network.
